Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.75 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.75 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.75 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | KHK | P50053 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10709797 | 0.90 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DCCNE1 | |
| SCHEMBL292710 | 0.85 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCCNE1 | |
| SCHEMBL29824397 | 0.85 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCCNE1 | |
| SCHEMBL291798 | 0.83 | PDE4A (0.96) | PDE4APDE4BPDE4CPDE4DCCNE1 | |
| SCHEMBL3538019 | 0.83 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DKHK | |
| SCHEMBL6395182 | 0.78 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10870009 | 0.78 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DKHK | |
| SCHEMBL10705672 | 0.77 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DCCNE1 | |
| SCHEMBL10713846 | 0.77 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10870316 | 0.77 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DKHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718654-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-18 | — | — | US | disclosed |
| EP-1819707-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058867-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116371-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116371-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | PDE4A 1428/4885PDE4B 1709/4885PDE4C 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.